Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Hope Rugo
Headshot of Hope Rugo
Hope Rugo

Description

Summary

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood.

This research study involves the following investigational drugs:

  • Sacituzumab govitecan
  • Atezolizumab

Official Title

A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)

Details

Keywords

Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA, Breast Neoplasms, Triple Negative Breast Neoplasms, Residual Neoplasm, Recurrence, Atezolizumab, Sacituzumab govitecan, Atezolizumab and Sacituzumab govitecan

Eligibility

Locations

  • UCSF
    San Francisco California 94115 United States
  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
    New Lenox Illinois 60451 United States

Lead Scientist at UCSF

  • Hope Rugo
    Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dana-Farber Cancer Institute
ID
NCT04434040
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 40 people participating
Last Updated